The first patients have been enrolled in 4SIGHT, a global phase 3 trial comparing a single intravitreal injection of the investigational gene therapy 4D-150 with aflibercept 2 mg ...

Please provide your email address to receive an email when new articles are posted on . Topline results from a phase 1 extension study show EO2002, a nonsurgical cell therapy for corneal edema, ...

Researchers sought to determine whether BCVA and ocular symptoms could help determine dosing for belantamab mafodotin in patients with r/r multiple myeloma. The following article features coverage ...

Fundus photographs of eyes with diabetic macular edema (DME) could be used to estimate best-corrected visual acuity (BCVA) when artificial intelligence examines the pictures. Best-corrected visual ...

Rates of PDR, vitreous hemorrhage, and discontinuations due to adverse events were higher with remigromig than ranibizumab.

5-Hydroxymethylcytosines in circulating cell-free DNA and overall survival in patients with multiple myeloma. Isatuximab plus carfilzomib and dexamethasone in patients with relapsed multiple myeloma ...